Table 2 The baseline clinical characteristics of MS patients
Clinical characteristics | MS cases in remission (n = 30) | MS cases in relapse (n = 30) | P value |
|---|---|---|---|
Age of onset (years) | 0.938 | ||
Mean ± SD | 26.5 ± 7.7 | 26.6 ± 7.1 | |
Range (min–max) | (15–40) | (15–44) | |
Duration of illness (years) | 0.478 | ||
Mean ± SD | 5.1 ± 4.7 | 4.3 ± 4.3 | |
Range (min–max) | (1–17) | (1–18) | |
Number of relapses in the last 2 years | 0.580 | ||
Mean ± SD | 1.5 ± 0.7 | 1.6 ± 0.6 | |
Range (min–max) | (0–3) | (1–3) | |
Total number of relapses | 0.371 | ||
Mean ± SD | 3.1 ± 1.9 | 2.1 ± 1.4 | |
Range (min–max) | (1–8) | (1–6) | |
EDSS | 0.970 | ||
Mean ± SD | 2.89 ± 1.3 | 2.95 ± 1.6 | |
Range (min–max) | (1–5) | (1–7) | |
Immunomodulatory therapy no. (%) | 0.045* | ||
Monthly methylprednisolone | 17 (56.7%) | 21 (70%) | |
Intramuscular interferon beta-1a | 7 (23.3%) | 1 (3.3%) | |
Subcutaneous interferon beta-1b | 2 (6.7%) | 6 (20%) | |
Subcutaneous interferon beta-1a | 4 (13.3%) | 2 (6.7%) |